Ginkgo Bioworks earnings miss, Revenue beats in Q3
Investing.com - Ginkgo Bioworks reported on Monday third quarter {{erl-1173150||earnings that missed analysts' forecasts and revenue that topped expectations. Ginkgo Bioworks announced...
-
-
Ginkgo Bioworks Misses Q3 EPS by 12c
Ginkgo Bioworks (DNA) reported Q3 EPS of ($0.41), $0.12 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $66.4 million versus the consensus estimate of $60.35...
-
Cathie Wood’s Dip-Buying Binge Mainly Focusing on Small Stocks
(Bloomberg) -- Cathie Wood’s latest dip-buying binge appears to be largely focused on smaller stocks, cementing her firm’s already hefty shareholdings in such companies.Barring a few...
-
Pre-Open Movers: Walmart Gains Following Earnings Beat, Zoom Falls on Downgrade
Pre-Open Stock Movers:Ginkgo Bioworks (DNA) 22% HIGHER; reported Q2 EPS of ($0.41), $0.36 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $145 million versus...
-
Dow Futures Ease Ahead of Major Retailer Earnings
By Oliver Gray Investing.com - U.S. stock futures were trading slightly lower during Monday's evening deals, after major benchmark averages finished the regular session higher as investors...
-
After-Hours Movers: Ginkgo Bioworks, Fabrinet Gain Post Earnings; ZipRecruiter Drops
After-Hours Stock Movers: Ginkgo Bioworks (NYSE:DNA) 23% HIGHER; {{erl-1173150||reported Q2 EPS of ($0.41), $0.36 worse than the analyst estimate of ($0.05). Revenue for the quarter came in...
-
Ginkgo Bioworks Lifts Guidance After Mixed Q2 Results; Shares Surge
By Yasin Ebrahim Investing.com -- Ginkgo Bioworks lifted its full-year guidance after reporting mixed second-quarter results. Losses were wider than expected as rising costs offset...
-
Ginkgo Bioworks Misses Q2 EPS by 36c, Raises Guidance
Ginkgo Bioworks (DNA) reported Q2 EPS of ($0.41), $0.36 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $145 million versus the consensus estimate of $78.83...
-
Ginkgo Bioworks Q1 Revenues Beat; Guides Higher
Ginkgo Bioworks (DNA) reported Q1 revenue $168 million versus the consensus estimate of $105.68 million.GUIDANCE:Ginkgo Bioworks sees FY2022 revenue of $375-390 million, versus the consensus...
-
Pre-Open Stock Movers 03/29: (NLSN) (LOVE) (EVTL) Higher; (NEO) (PROG) (CONN) Lower (more...)
Pre-Open Stock Movers:NeoGenomics, Inc. (NASDAQ:NEO) 29% LOWER; CEO Mark Mallon to step down. Expects revenue for Q1 2022 may be below the low end of its prior guidance of $118 - $120...
-
Ginkgo Bioworks (DNA) Q4 Revenue Tops Consensus
Ginkgo Bioworks (DNA) reported Q4 EPS of ($1.10), $1.06 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $148.5 million versus the consensus estimate of $94.81...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
